189 articles about uniQure
uniQure to Participate in Upcoming Industry Conferences in November
uniQure N.V. today announced its participation in the following upcoming investor and scientific conferences: The 28th Annual Meeting of the Huntington Study Group (Virtual), November 4 - 6, 2021
uniQure Announces the Appointment of Rachelle Jacques to its Board of Directors
uniQure N.V., a leading gene therapy company advancing transformative therapies for patients with severe medical needs, announced the appointment of Rachelle Jacques to its Board of Directors.
uniQure to Participate in Multiple Upcoming Industry Conferences in October
uniQure N.V. today announced its participation in the following upcoming investor and scientific conferences: Chardan’s 5th Annual Genetic Medicines Conference, October 4 - 5, 2021
uniQure to Participate in Multiple Upcoming Industry Conferences in September 2021
uniQure N.V., a leading gene therapy company advancing transformative therapies for patients with severe medical needs, announced its participation in the following upcoming investor and scientific conferences.
The oncogenicity and neurotoxicity risks of AAVs and possible mitigation strategies were the primary focus on Thursday.
uniQure Announces Completion of Additional Patient Procedures Following Positive Recommendation from Data Safety Monitoring Board in Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease
uniQure N.V., a leading gene therapy company advancing transformative therapies for patients with severe medical needs, announced that two additional patient procedures have been completed in the second, higher-dose cohort in the Phase I/II clinical trial of AMT-130 for the treatment of Huntington’s disease.
While treatments exist to manage the symptoms of the disease, nothing has proven to be curative – yet. Several biopharma companies are working hard to change that.
uniQure Announces Second Quarter 2021 Financial Results and Highlights Recent Company Progress
uniQure N.V., a leading gene therapy company advancing transformative therapies for patients with severe medical needs, reported its financial results for the second quarter of 2021 and highlighted recent progress across its business.
Why not take advantage of the perks of a lower cost of living, slower pace, and opportunities to make a big impact in some important disease areas?
uniQure has acquired Corlieve with upfront cash of approx. $55 million and will center on the latter's lead program, AMT-260, an advanced treatment for TLE.
CSL Behring Announces Closing of Global Commercialization and License Agreement with uniQure for etranacogene dezaparvovec
Global biotherapeutics leader CSL Behring announced the closing of its global Commercialization and License agreement with uniQure for etranacogene dezaparvovec, a novel gene therapy for the treatment of hemophilia B. Etranacogene dezaparvovec is currently in Phase 3 clinical trials and has been shown to result in near-normal levels of Factor IX – the blood clotting protein lacking in people with hemophilia B. CSL Behring has been recognized as a global hematology leader for decades.
Clinical Catch-Up: April 26-30
5/3/2021Although clinical trial news related to COVID-19 was slow last week, there’s quite a bit of news on studies for other indications.
There is hope for uniQure’s HOPE-B trial after all. Shares of uniQure NV are climbing this morning after the company announced the clinical hold on its hemophilia B gene therapy has been lifted by the U.S. Food and Drug Administration.
Clinical Catch-Up: March 29-April 2
4/5/2021It was a busy week for clinical trial news. Here’s a look.
An investigation was conducted by an independent laboratory and reviewed by leading external experts in the field.
The FDA put a clinical hold on UniQure's Phase III trial after a high-risk participant developed liver cancer.
In a shining moment that signaled hope for hemophilia B patients, uniQure presented data on Tuesday showing that its gene therapy treatment, etranacogene dezaparvovec (AMT-061), substantially increased production of the blood-clotting protein factor IX in nearly all pivotal Phase III HOPE-B trial...
Positive top-line data from UniQure’s Phase III HOPE-B gene therapy trial of etranacogene dezaparvove, an investigational AAV5-based gene therapy, point to a potentially curative treatment for patients with moderate to moderately severe hemophilia B.
In June, it dosed its first two patients using a novel therapeutic, AMT-130, delivered directly to the brain. Initial readouts are expected in a year’s time.
uniQure Announces Publication of Positive Interim Data from Phase IIb Clinical Trial of Etranacogene Dezaparvovec
uniQure N.V. announced the publication of 26-week interim data from the ongoing Phase IIb clinical trial of etranacogene dezaparvovec, an investigational gene therapy for hemophilia B, in the journal, Blood Advances.